Abstract

Animal models have suggested that glutamate neurotoxicity or metabolic impairment may cause neurodegeneration in HD. Remacemide, a drug with glutamate antagonist properties, has been safely tested in HD patients. Co-Enzyme Q10, a metabolic enhancer, has shown preliminary success in reversing metabolic markers of HD. This double-blind, This research study will evaluate the effects of Co-enzyme Q10 and Remacemide on the symptoms of Huntington's Disease (HD). The brain cell death that is the cause of HD is thought to be possibly caused by a) over-activity of the natural brain chemical glutamate, b) a lack of normal cell energy, or c) harmful brain substances called free radicals. Remacemide is an experimental drug that may be useful in treating HD by adjusting the activity of glutamate in the brain. Co-enzyme Q10 (CoQ) is a marketed product that may be useful in HD because it increases cell energy and decreases free radicals. This study will evaluate the potential benefits and safety of remacemide and CoQ, alone or in combination, on the features of HD.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR007122-09
Application #
6309916
Study Section
Project Start
1999-12-01
Project End
2001-02-28
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
9
Fiscal Year
2000
Total Cost
$38,800
Indirect Cost

  Institution

Name
Wake Forest University Health Sciences
Department
Type
DUNS #
041418799
City
Winston-Salem
State
NC
Country
United States
Zip Code
27106

  Publications

Paek, M-S; Nightingale, C L; Tooze, J A et al. (2018) Contextual and stress process factors associated with head and neck cancer caregivers' physical and psychological well-being. Eur J Cancer Care (Engl) 27:e12833
South, Andrew M; Nixon, Patricia A; Chappell, Mark C et al. (2018) Obesity is Associated with Higher Blood Pressure and Higher Levels of Angiotensin II but Lower Angiotensin-(1-7) in Adolescents Born Preterm. J Pediatr :
Askie, Lisa M; Darlow, Brian A; Finer, Neil et al. (2018) Association Between Oxygen Saturation Targeting and Death or Disability in Extremely Preterm Infants in the Neonatal Oxygenation Prospective Meta-analysis Collaboration. JAMA 319:2190-2201
Keaton, Jacob M; Gao, Chuan; Guan, Meijian et al. (2018) Genome-wide interaction with the insulin secretion locus MTNR1B reveals CMIP as a novel type 2 diabetes susceptibility gene in African Americans. Genet Epidemiol 42:559-570
Autmizguine, Julie; Tan, Sylvia; Cohen-Wolkowiez, Michael et al. (2018) Antifungal Susceptibility and Clinical Outcome in Neonatal Candidiasis. Pediatr Infect Dis J 37:923-929
Jilling, Tamas; Ambalavanan, Namasivayam; Cotten, C Michael et al. (2018) Surgical necrotizing enterocolitis in extremely premature neonates is associated with genetic variations in an intergenic region of chromosome 8. Pediatr Res 83:943-953
South, Andrew M; Nixon, Patricia A; Chappell, Mark C et al. (2018) Association between preterm birth and the renin-angiotensin system in adolescence: influence of sex and obesity. J Hypertens 36:2092-2101
Hong, Jaeyoung; Hatchell, Kathryn E; Bradfield, Jonathan P et al. (2018) Transethnic Evaluation Identifies Low-Frequency Loci Associated With 25-Hydroxyvitamin D Concentrations. J Clin Endocrinol Metab 103:1380-1392
Srinivasan, Lakshmi; Page, Grier; Kirpalani, Haresh et al. (2017) Genome-wide association study of sepsis in extremely premature infants. Arch Dis Child Fetal Neonatal Ed 102:F439-F445
Brinkley, Tina E; Leng, Xiaoyan; Nicklas, Barbara J et al. (2017) Racial differences in circulating levels of the soluble receptor for advanced glycation endproducts in middle-aged and older adults. Metabolism 70:98-106

Showing the most recent 10 out of 577 publications